oasis 1 trial oral semaglutide 50 mg obesity lancet 2023 Orforglipron, an small-molecule GLP-1 receptor agonist, for the treatment of in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled Obesity pharmacotherapy in older adults:

At the 12 mg dose, participants lost an average of roughly 70 pounds, Lilly said

Although not specifically examining the role of glucosinolates, these studies demonstrate the potential importance of a diet rich in glucosinolates for musculoskeletal health

An interesting possibility for men: as body fat decreases, natural testosterone production may increase

Think lean proteins, cooked vegetables, and simple carbohydrates

Wegovy is a weekly injection prescribed to people with obesity or those who are overweight (a BMI of 27 or more) who have at least one weight-related health condition, such as hypertension or type 2 diabetes (2)